Form 4: Apogee Director's Entity Acquires Warrants

Apogee Therapeutics director Nimish Shah reported the indirect acquisition of 365,853 pre-funded warrants through Venrock Opportunities Fund, L.P., signaling confidence in the company's future.

Summary

• Nimish P Shah, a Director of Apogee Therapeutics, Inc. (APGE), reported the indirect acquisition of 365,853 pre-funded warrants.
• The transaction date for the acquisition is listed as October 10, 2025.
• The warrants were acquired by Venrock Opportunities Fund, L.P. (VOF), where Nimish Shah is a voting member of its general partner, Venrock Opportunities Management, LLC.
• Each pre-funded warrant has an exercise price of $0.00001 per share.
• The price paid for each derivative security (warrant) was $40.9999.
• The warrants are immediately exercisable and have no expiration date.
• VOF is restricted from exercising the warrants if it would cause their aggregate beneficial ownership to exceed 4.99% of Apogee Therapeutics' total issued and outstanding common stock.
• Nimish Shah expressly disclaims beneficial ownership over shares held by VOF, except to the extent of his indirect pecuniary interests.

Sentiment

Score: 7

Explanation: The indirect acquisition of a significant number of pre-funded warrants by an entity associated with a director signals strong confidence in the company's future prospects, despite the indirect nature of the ownership and the future transaction date.

Positives

• The indirect acquisition of a significant number of pre-funded warrants by an entity associated with a director signals strong insider confidence in the company's future prospects.
• The very low exercise price of $0.00001 per share makes the warrants highly attractive for conversion into common stock, indicating a belief in substantial upside potential.
• The immediate exercisability and lack of an expiration date provide flexibility for the warrant holder.

Negatives

• The ownership is indirect, meaning the director's personal conviction is channeled through an investment fund, which may differ from a direct personal investment.
• A beneficial ownership cap of 4.99% restricts the extent to which Venrock Opportunities Fund, L.P. can exercise the warrants, potentially limiting immediate full conversion.

Risks

• The 4.99% beneficial ownership limitation could prevent Venrock Opportunities Fund, L.P. from fully exercising all 365,853 warrants if it exceeds the threshold, potentially impacting their ability to realize full value.
• Future dilution risk for existing shareholders if and when these warrants are exercised and converted into common stock.

Future Outlook

The acquisition of pre-funded warrants by an entity associated with a director suggests a positive long-term outlook for Apogee Therapeutics, as these instruments are typically acquired with an expectation of future stock price appreciation.

Industry Context

Insider transactions, such as the acquisition of warrants by a director's associated entity, are closely monitored by the market as they can signal management's confidence in the company's future performance, often preceding significant developments or positive trends within the biotechnology or pharmaceutical industry.

Related Party Transactions

• The transaction involves Venrock Opportunities Fund, L.P., an entity where Director Nimish Shah is a voting member of its general partner, Venrock Opportunities Management, LLC. This constitutes an indirect related party transaction.

Stakeholder Impact

• Shareholders may view this as a positive signal of confidence from an informed insider, potentially leading to increased investor interest.
• Potential for future dilution if and when the warrants are exercised and converted into common stock.

Next Steps

• Potential future exercise of the pre-funded warrants by Venrock Opportunities Fund, L.P., subject to the 4.99% beneficial ownership limitation.

Key Dates

Recommendation

The indirect acquisition of 365,853 pre-funded warrants by an entity where a director holds a voting interest suggests strong insider confidence in Apogee Therapeutics' future value. The low exercise price combined with the significant investment in the warrants themselves indicates a belief in substantial upside potential, making it a positive signal for investors.

Keywords

Apogee Therapeutics, APGE, Nimish Shah, Form 4, Insider Transaction, Pre-Funded Warrants, Venrock, Beneficial Ownership, Equity Acquisition